Physician profile
Deepak Bommisetty
NPI 1922454982
$1,900.89
in general payments reported to CMS, 2019-2025
11 companies · $47.39 in 2025
The $47.39 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $112 · 2021: $637 · 2022: $505 · 2023: $35.97 · 2024: $259 · 2025: $47.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $654.50 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.47 | 2019-2022 | |
| Pfizer INC. | $269.15 | 2019-2024 | |
| Shockwave Medical, INC | $146.03 | 2022 | |
| Abbott Laboratories | $145.93 | 2021 | |
| Amarin Pharma, INC. | $124.21 | 2019 | |
| Abbvie INC. | $117.34 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.35 | 2022-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $25.12 | 2024 | Zerbaxa, Dificid |
| Astrazeneca Pharmaceuticals Lp | $19.23 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $16.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Bommisetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.